跳至主要内容
临床试验/KCT0004437
KCT0004437已完成未知

Clinical research of comparative effectiveness and safety of JHG002 for chronic temporomandibular joint dysfunction: A multicenter randomized controlled trial)

Jaseng Medical Foundation0 个研究点目标入组 82 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
82

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
19(Year) 至 70(Year)(—)
性别
All

入选标准

  • (1) Patients with unilateral or bilateral TMJ pain
  • (2) Patients with VAS = 40mm for the area showing TMJ pain (for patients with bilateral pain, the side with worse pain)
  • (3) Patients complaining of persistent of sporadic TMJ pain for at least 3 months
  • (4) Patients diagnosed as myofascial TMD (Axis I: Group 1) based on the RDC/TMD diagnostic criteria [5]
  • (5) Patients aged 19–70 years on the date they sign the consent form
  • (6) Patients who provide consent to participate in the trial and return the informed consent form

排除标准

  • (1) Patients whose current pain episode developed or worsened because of a road traffic accident or traumatic injury
  • (2) Patients diagnosed in Group 2 or 3 of Axis I based on the RDC/TMD diagnostic criteria
  • (3) Patients who have undergone surgery related to the TMJ
  • (4) Patients with other chronic diseases that could interfere with interpretation of the treatment effects or outcomes (e.g., rheumatoid arthritis, neoplastic disease, stroke, or myocardial infarction)
  • (5) Patients currently taking steroids, immunosuppressants, psychiatric drugs, or other drugs that could affect the study results
  • (6) Patients who have received HPP within the last month, or who have taken drugs that could affect pain, such as NSAIDs, within the last week
  • (7) Pregnant or breastfeeding women
  • (8) Patients who have finished participation in another clinical trial within the last month, who participated in another trial within 6 months of selection, or who are planning to participate in another clinical trial during the follow-up period
  • (9) Patients with a history of hypersensitivity after HPP
  • (10) Diabetic patients with uncontrolled blood glucose (fasting blood glucose = 180mg/dl)
  • (11) Patients with aspartate aminotransferase or alanine aminotransferase at least 2 times the normal range at the testing centre
  • (12) Patients with creatinine at least 2 times the normal range at the testing centre
  • (13) Patients suspected to have organic disease
  • (14) Patients with cardiac, hepatic, renal, or other serious complications
  • (15) Patients with psychogenic disease
  • (16) Patients who is taking warfarin
  • (17) Patients with pacemaker
  • (18) Patients who are unable to receive pharmacopuncture due to e.g., inflammation or a wound at the relevant acupoints
  • (19) Patients whose participation in the trial is judged by a researcher to be problematic

研究者

相似试验

Effectiveness and safety of JHG002 for chronic... | 临床试验